Latano-Vision (Latanoprost)

Latanoprost is used to lower intra‑ocular pressure in ocular conditions that involve impaired aqueous humor outflow.

• Open-angle glaucoma: reduces intra‑ocular pressure, helping to prevent progressive optic nerve damage.
• Ocular hypertension: lowers eye pressure to reduce the risk of developing glaucoma.
• Secondary open-angle glaucoma: improves fluid drainage, contributing to pressure control in cases secondary to other ocular diseases.

• Latanoprost is a synthetic analogue of prostaglandin F₂α that binds to FP receptors on the ciliary muscle and scleral tissue. Activation of these receptors remodels extracellular matrix, increasing uveoscleral outflow of aqueous humor, which results in a sustained reduction of intra‑ocular pressure. The drug’s selective FP‑receptor agonism produces minimal effect on aqueous humor production, focusing its action on the outflow pathway.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects

• Eye redness: mild conjunctival hyperemia.
• Increased eyelash growth: longer, thicker lashes.
• Darkening of iris color: gradual brown pigmentation.
• Eye irritation or foreign‑body sensation.

Serious or Rare Side Effects

• Uveitis or intra‑ocular inflammation: requires immediate medical attention.
• Macular edema: rare but vision‑threatening.

When prescribing or using Latano‑Vision, several precautions should be observed to ensure safety and efficacy.

• Monitor intra‑ocular pressure: schedule regular ophthalmic examinations to assess response.
• Assess for ocular inflammation: discontinue if severe uveitis or iritis develops.
• Avoid contact lens wear: the formulation may cause deposits; remove lenses before instillation.
• Use with caution in patients with a history of ocular surgery or corneal disease.
• Pregnancy and lactation: safety not established; discuss risks with a healthcare professional.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic or systemic agents, influencing its efficacy or safety.

Major Interactions (Avoid)

• Concomitant use with other prostaglandin analogs: additive pressure‑lowering may cause hypotony.
• Use with ocular anesthetics containing preservatives: increased risk of corneal irritation.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory eye drops: may reduce prostaglandin effect.
• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive intra‑ocular pressure reduction.
• Beta‑blocker eye drops: combined IOP‑lowering effect may be excessive.
• Anticholinergic eye drops: potential for reduced outflow enhancement.